To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects

NCT06705998 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

52

Enrollment

NETWORK

Sponsor class

Conditions

NASH

Interventions

DRUG: BAR502 single dose
DRUG: Placebo single dose
DRUG: BAR502 multiple doses

Sponsor

BAR Pharmaceuticals s.r.l.